Stock VRDN VIRIDIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
14.6 USD -3.69% Intraday chart for Viridian Therapeutics, Inc. -8.12% -32.97%
Apr. 16 Foghorn Therapeutics Names Kristian Humer CFO MT
Mar. 21 B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Foghorn Therapeutics Names Kristian Humer CFO
MT
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
PR
B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers
MT
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
BU
Wedbush Lifts Viridian Therapeutics' PT to $40 From $39 on Higher Net Cash, Keeps Outperform Rating
MT
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q4 Revenue $72,000
MT
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
AQ
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer
MT
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
BU
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer
CI
Viridian Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Wedbush Trims Viridian Therapeutics' Price Target to $39 From $40, Keeps Outperform Rating
MT
Viridian Therapeutics Prices Common Stock Offering at $21 per Share
MT
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. News Viridian Therapeutics, Inc.